Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Crohn’s Disease Treatment Industry?

The market size of Crohn’s disease treatment has experienced robust growth in the recent past. The market will witness an increase from $12.45 billion in 2024 to $13.1 billion in 2025 with a compound annual growth rate (CAGR) of 5.2%. The growth during the past periods is due to factors such as the rise in disease prevalence, progress in diagnostic methods, adoptation of biological therapies, heightened patient awareness and education, as well as developments in clinical research.

In the ensuing years, the market for Crohn’s disease treatment is expected to experience robust expansion. It is projected to reach “$17.34 billion by 2029, growing at a compounded annual growth rate (CAGR) of 7.3%.” The predicted growth in this timeframe can be attributed to factors such as the rise of personalized medicine, the expansion of the biologics market, evolving treatment guidelines, increased healthcare expenditures, and joint research initiatives. During the forecast period, significant trends include the use of telemedicine for patient care management, research into immune modulation strategies, patient-focused care models, and digital health solutions integration.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp

What Forces Are Driving The Growth Of The Crohn’s Disease Treatment Industry?

The escalating occurrence of inflammatory bowel disorders is anticipated to drive the progression of the Crohn’s disease treatment market in the future. These disorders constitute a collection of chronic ailments associated with inflammation in the gastrointestinal tract. They can lead to inflammations and damage anywhere in the digestive system, from mouth to anus. The principle behind Crohn’s disease treatment is to decrease this intestinal inflammation, inhibit symptom flare-ups, and maintain remission. For example, in September 2023, the National Center for Biotechnology Information, a US-based government entity, reported a similar rise in the frequency of Crohn’s disease and ulcerative colitis. Inflammatory bowel disease was forecasted to be 825 cases per 100,000 residents in 2023—410 for Crohn’s disease and 414 for ulcerative colitis and IBD-u. Consequently, the surge in these disorders is accelerating the expansion of the Crohn’s disease treatment market.

What Is The Overview Of Market Segmentation In The Crohn’s Disease Treatment Industry?

The crohn’s disease treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics

2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates

3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids

4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine

5) By Other Drug Types: Biologics, Small Molecules, Other Treatments

Which Emerging Trends And Strategic Shifts Are Shaping The Crohn’s Disease Treatment Market?

Leading players in the Crohn’s disease treatment market are developing and acquiring approvals for new medications, for example, the biosimilar ustekinumab, aiming to enhance the effectiveness and accessibility of treatment for patients, leading to improved patient wellbeing and standard of life. Biosimilar ustekinumab is a biological medication closely comparable to the original ustekinumab (an antibody-based drug) employed for treating autoimmune ailments. For instance, Sandoz International GmbH, a pharmaceutical enterprise based in Switzerland, introduced Pyzchiva (ustekinumab) throughout Europe in July 2024. It is recognized as the first ustekinumab biosimilar obtainable in all potencies, comprising a 130 mg vial designed exclusively for patients with Crohn’s disease. This offering is recommended for adults and children over six years of age suffering from plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It not only enhances Sandoz’s immunology portfolio but also strives to boost the availability of economical treatments for chronic inflammatory diseases.

Who Are The Primary Players Operating Across The Global Crohn’s Disease Treatment Market?

Major companies operating in the crohn’s disease treatment market include AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Bristol-Myers Squibb Company, Galapagos NV, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Arena Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Which Region Offers The Most Growth Potential For The Crohn’s Disease Treatment Market Through 2029?

North America was the largest region in the global Crohn’s disease treatment market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the Crohn’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10852&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model